Business Wire

B2BROKER

18.4.2024 18:07:28 CEST | Business Wire | Press release

Share
B2Broker Increases Leverage on Major FX Pairs to 1:200

Leading Prime of Prime liquidity provider B2Broker is committed to quality, always listening to their clients' needs to provide them with the best possible tools to bring in more end users and gain a competitive edge in the industry. In this regard, B2Broker announces the rise of the leverage to 1:200 for major FX pairs, thereby reducing the margin requirements from 1% to 0.5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418556608/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2Broker increases leverage on major FOREX pairs to 1:200 and to 1:50 for BTC/USD and ETH/USD pairs, enhancing the market position of their clients. (Graphic: Business Wire)

Additionally, with the cryptocurrency market thriving and traders’ demands for higher leverage growing, the company has increased leverage up to 1:50 for BTCUSD and ETHUSD, reducing margin requirements from 10% to 2% and significantly enhancing the clients' market position.

Additional Information about B2Broker Liquidity Solutions

Having been in the industry for over a decade, B2Broker's liquidity solutions have significantly expanded. They currently offer over 1500 instruments across 8 asset classes, including FOREX, Crypto CFD, Spot Indices, Precious Metals, Single Stocks, ETFs, Commodities, and NDFs CFD.

B2Broker ensures access to deep liquidity pools from Tier-1 providers, facilitating tight spreads and ultra-fast execution. Advanced technology platforms and FIX API integrations like B2Trader, cTrader, oneZero, Prime XM, Centroid, TFB, TradeLocker, Your Bourse, FX Cubic, and MT4/MT5 allow for seamless connectivity across multiple trading systems. The infrastructure of B2Broker facilitates the distribution and aggregation of liquidity through various channels, enhancing trade execution and reducing risk.

The key strengths of the liquidity solutions include a robust infrastructure, extensive connectivity options, and the ability to develop customised liquidity setups to meet the client’s demands.

As an industry leader, B2Broker has introduced multiple innovative solutions throughout its journey. Last year, the company introduced NDFs as a new asset class in the form of CFDs, with the advantage of next-day settlements. Furthermore, they were the first in the market to introduce crypto CFDs based on spot and then perpetual futures LPs. And now, B2Broker proudly offers the most competitive margin conditions on the market!

The company has significantly strengthened its balance sheet by serving over 250 institutional clients and 30 professional funds. Because of this strong financial base, it has been able to expand leverage and meet clients' requests.

With the increased leverage on highly demanded trading pairs in key markets such as FX and Crypto, the company empowers brokers to give their traders greater flexibility in managing their capital, significantly broadening the client’s appeal to a larger user base.

John Murillo, Chief Dealing Officer of B2Broker Group of Companies, remarked:

“This strategic update not only enhances our clients' competitive edge but also augments their capacity to cater to the evolving demands of their clientele, attract new business, and elevate their service standards by leveraging our liquidity solutions.

Thanks to our robust balance sheet and extensive client base, coupled with our impressive trading volumes, we stand at the forefront of the market. Our innovative mindset has been evident throughout our journey. We were the first to introduce crypto CFDs based on spot and, later, on perpetual futures. In addition to FOREX, today, we proudly offer over 150 crypto CFD pairs, a testament to our commitment to innovation and meeting the diverse needs of our clients.”

Final Remarks

B2Broker is a distinguished leader in the FinTech sector, revolutionising the industry with significant contributions over the last decade. With a dedication to innovation and continuous improvement, the company guarantees that its clients stay ahead of the competition and set trends alongside it. Their vast ecosystem provides solutions that suit various business models.

In the latest update, B2Broker has substantially upgraded the leverage to provide the most competitive conditions for institutional clients, professional traders, brokerages, hedge funds, proprietary trading desks, and other financial institutions.

Contact B2Broker today for tailored solutions that drive success!

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418556608/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye